Long-term treatment for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a medication called povetacicept for long-term use in adults with IgA nephropathy, a kidney disease. If you've already completed the earlier study, this trial aims to see how well the drug works over a longer period to help keep your kidneys working longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the full 2-year (104-week) treatment period in the earlier study for this condition.
- Your kidney function must be at or above a certain level (eGFR of 15 or higher) within the last 45 days.
- You cannot be planning to join any other experimental drug trials while on this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This study looks at the long-term safety and effectiveness of atacicept in people with IgA nephropathy (IgAN) who have already completed treatment in a previous atacicept study. It is for patients who want to continue their care and see how well the medicine works over more time.
This study provides continuing treatment with iptacopan for people with IgA nephropathy who have completed a previous iptacopan trial. It aims to see how safe and tolerable the drug is over a longer period.
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
This study tests a medicine called telitacicept for children with IgA nephropathy or IgA vasculitis nephritis, two kidney diseases that cause protein in the urine. The goal is to see if the medicine can reduce protein loss and help protect the kidneys.
This study tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It is a long-term follow-up for people who already finished a previous study with this medicine, to see if it keeps working safely over time.
Hear when a new Immunoglobulin A Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.